215 related articles for article (PubMed ID: 26990170)
21. Ceftaroline for complicated skin and skin-structure infections.
Nannini EC; Stryjewski ME; Corey GR
Expert Opin Pharmacother; 2010 May; 11(7):1197-206. PubMed ID: 20402556
[TBL] [Abstract][Full Text] [Related]
22. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Morrissey I; Ge Y; Janes R
Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
24. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.
Flamm RK; Sader HS; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2012 Jun; 56(6):2933-40. PubMed ID: 22470115
[TBL] [Abstract][Full Text] [Related]
25. Treatment of infections due to resistant Staphylococcus aureus.
Anstead GM; Cadena J; Javeri H
Methods Mol Biol; 2014; 1085():259-309. PubMed ID: 24085702
[TBL] [Abstract][Full Text] [Related]
26. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
Farrell DJ; Flamm RK; Jones RN; Sader HS
Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
Karlowsky JA; Adam HJ; Decorby MR; Lagacé-Wiens PR; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2011 Jun; 55(6):2837-46. PubMed ID: 21402844
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
Vidaillac C; Leonard SN; Rybak MJ
Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
[TBL] [Abstract][Full Text] [Related]
29. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae.
Moisan H; Pruneau M; Malouin F
J Antimicrob Chemother; 2010 Apr; 65(4):713-6. PubMed ID: 20097788
[TBL] [Abstract][Full Text] [Related]
30. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program.
Flamm RK; Sader HS; Farrell DJ; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S194-205. PubMed ID: 22903952
[TBL] [Abstract][Full Text] [Related]
31. Sustained antimicrobial activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States Medical Centers from 2004 through 2008.
Putnam SD; Sader HS; Farrell DJ; Jones RN
J Chemother; 2010 Feb; 22(1):13-6. PubMed ID: 20227986
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.
Keel RA; Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2011 Sep; 55(9):4028-32. PubMed ID: 21670184
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in immunocompromised cancer patients undergoing chemotherapy in Pakistan.
Younus A; Faiz M; Saleem M; Saghir S
J Chemother; 2009 Feb; 21(1):31-5. PubMed ID: 19297269
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).
Sader HS; Moet GJ; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202
[TBL] [Abstract][Full Text] [Related]
35. Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms.
Kunz Coyne AJ; Stamper K; Bleick C; Kebriaei R; Lehman SM; Rybak MJ
Microbiol Spectr; 2024 Apr; 12(4):e0321223. PubMed ID: 38411110
[TBL] [Abstract][Full Text] [Related]
36. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
37. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
Jacqueline C; Amador G; Batard E; Le Mabecque V; Miègeville AF; Biek D; Caillon J; Potel G
J Antimicrob Chemother; 2011 Apr; 66(4):863-6. PubMed ID: 21393213
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
Werth BJ; Steed ME; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.
MacVane SH; So W; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2014 Dec; 58(12):7520-6. PubMed ID: 25288076
[TBL] [Abstract][Full Text] [Related]
40. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
Zhanel GG; Sniezek G; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2009; 69(7):809-31. PubMed ID: 19441869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
